Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Ulta Beauty Inc (ULTA) Price & Performance

Eli Lilly And CoTrade
Ulta Beauty IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Ulta Beauty Inc — how do they compare? Eli Lilly And Co trades at $1,215.18 (market cap $1.08T), while Ulta Beauty Inc trades at $534 (market cap $23.27B). The key difference: Eli Lilly And Co is far larger — about 46.4× Ulta Beauty Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.

LLYULTA
Market Cap
$1.08T$23.27B
Sector
HealthConsumer Cyclical
52-Week High
$1.24K$706.82
52-Week Low
$639.43$450.75
Enterprise Value
$1.13T$25.35B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Ulta Beauty Inc

Ulta Beauty (ULTA) trades at $537.69, down 2.0% today, with a bullish technical outlook from moving averages and a consensus analyst price target of $618.29. Recent earnings show mixed quarterly beats, with Q1 2026 EPS of $7.74 exceeding expectations, while revenue growth remains steady at $11.3B for 2025. The company maintains strong profitability with a net margin of 9.36% and ROE of 47.45%, supported by an omnichannel strategy highlighted in recent news.

The stock presents a buy opportunity with Wall Street optimism (56.53% buy ratings) and solid fundamentals, but risks include margin compression from rising costs and competitive pressures. Near-term catalysts include the Q2 2026 earnings report, with expected EPS of $6.17, and the transition from the Target partnership, viewed as a growth opportunity by analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Ulta Beauty Inc

With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.

Read more on ULTA